This content is machine translated Cardiovascular risk and obesity Pathomechanisms, secondary prevention and treatment options Obesity is not only a well-known, significant risk factor for the development and progression of cardiovascular disease (CVD), but is also recognized as a disease entity in its own right...… CME-Test
View Post 19 min This content is machine translated Cardiovascular risk and obesity Pathomechanisms, secondary prevention and treatment options Obesity is not only a well-known, significant risk factor for the development and progression of cardiovascular disease (CVD), but is also recognized as a disease entity in its own right...… CME-Test
View Post 3 min This content is machine translated Heart failure in the light of the latest evidence MRAs offer advantages across the entire EF spectrum At the swissESCupdate, cardiology experts summarized important content from this year’s Annual Meeting of the European Society of Cardiology . In the area of heart failure, studies on the use…
View Post 3 min This content is machine translated Metabolic disorders and heart failure Cardiac metabolism in old age: effects and consequences Cardiovascular disease, particularly coronary artery disease (CAD) and heart failure (HF), is common in the ageing population and is one of the leading causes of death worldwide. With age, the…
View Post 5 min This content is machine translated Chronic heart failure Recognize early and initiate intervention The incidence and prevalence of chronic heart failure are positively correlated with age, although there are other risk factors such as obesity, diabetes and hypertension. In addition to the treatment…
View Post 4 min This content is machine translated Type 2 diabetes Cardiovascular optimized therapy up-to-date The current ESC guideline recommends blood glucose-lowering substances with a proven cardiovascular benefit for certain risk groups among type 2 diabetics. In type 2 diabetes (T2D) and atherosclerotic cardiovascular disease…
View Post 8 min This content is machine translated Heart failure: ESC guideline update 2023 Therapy-relevant new evidence on the entire EF spectrum The update of the ESC guideline on the treatment of heart failure includedthe results of large randomized studies that were not published until after the guideline was published in 2021.…
View Post 14 min This content is machine translated Heart failure Interventional treatment of the tricuspid valve Long considered the “forgotten valve,” the tricuspid valve (TC) has gained increasing attention and recognition in recent years. This is due in no small part to the development of new… CME-Test
View Post 4 min This content is machine translated Acute myocardial infarction and heart failure in young diabetics Type 2 with a poor risk profile for CVD Type 1 and type 2 diabetes differ in many ways, but both types are strongly associated with a high risk of cardiovascular complications. T2D at a young age is considered…
View Post 5 min This content is machine translated Heart failure and type 2 diabetes SGLT-2-i now recommended for the entire LVEF spectrum Based on data from large clinical trials, it is currently recommended that all patients with diabetes and chronic heart failure – regardless of left ventricular ejection fraction – are treated…
View Post 4 min This content is machine translated SGLT2i for heart failure HF prevalence in diabetes patients is underestimated in everyday clinical practice SGLT2 inhibitors can significantly reduce the risk of hospitalization for heart failure (HF) and death from cardiovascular causes in patients with diabetes and HF. However, the diagnosis of HF is…
